Volume 18, Issue 41, January - June, 2024

Decoding facial paralysis: Investigating potential small molecules for Moebius syndrome therapy

Sheilina Choudhary

School of Bioengineering and Food Technology, Shoolini University, Solan, India

ABSTRACT

Objective: The goal of this study is to conduct a thorough assessment of current knowledge about Moebius syndrome, including clinical symptoms, etiology, and related disorders. The study intends to investigate existing knowledge on prospective medication treatments for the treatment of Moebius syndrome, focusing on efficacy, safety, and symptom relief. This study aims to provide insights into the current state of pharmacological research for Moebius syndrome and identify prospective avenues for future research by reviewing the available literature and synthesizing the findings. The ultimate goal is to contribute to developing viable pharmaceutical methods to improve the quality of life for people with Moebius syndrome. Methods: In this investigation, target proteins were downloaded from the PDB and docked in Biovia. The ligands' and standard medications' binding affinity with each target protein was compared and assessed. Also, only 4 substances were chosen for SWISS-ADME final results. Results: The docking result revealed that the ligands selected have the best binding affinity with all the four target proteins. Conclusion: The ligands could potentially be used to treat Moebius Syndrome in the future approaches for studying the urge ligands in vitro and in vivo analysis to create novel Moebius’s inhibitors.

Keywords: Moebius syndrome, cranial nerves, facial paralysis, eye movement problems, speech and swallowing problems, limb deformities, prognosis

Drug Discovery, 2024, 18(41), e2dd1962

PDF

DOI: https://doi.org/10.54905/disssi.v18i41.e2dd1962

Published: 24 January 2024